CA2911309A1 - Sobetirome in the treatment of myelination diseases - Google Patents

Sobetirome in the treatment of myelination diseases

Info

Publication number
CA2911309A1
CA2911309A1 CA2911309A CA2911309A CA2911309A1 CA 2911309 A1 CA2911309 A1 CA 2911309A1 CA 2911309 A CA2911309 A CA 2911309A CA 2911309 A CA2911309 A CA 2911309A CA 2911309 A1 CA2911309 A1 CA 2911309A1
Authority
CA
Canada
Prior art keywords
disease
sobetirome
pharmaceutically acceptable
acceptable salt
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2911309A
Other languages
English (en)
French (fr)
Inventor
Meredith HARTLEY
Andrew PLACZEK
Marco RIGHI
Dennis Bourdette
Gail Marracci
Priya CHAUDHARY
Thomas S. Scanlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
US Department of Veterans Affairs
Original Assignee
Oregon Health and Science University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, US Department of Veterans Affairs filed Critical Oregon Health and Science University
Publication of CA2911309A1 publication Critical patent/CA2911309A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2911309A 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases Abandoned CA2911309A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
US61/819,467 2013-05-03
USPCT/US2013/0053640 2013-08-05
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (1)

Publication Number Publication Date
CA2911309A1 true CA2911309A1 (en) 2014-11-06

Family

ID=51843844

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2911309A Abandoned CA2911309A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Country Status (12)

Country Link
US (3) US10226438B2 (enExample)
EP (1) EP2991670B8 (enExample)
JP (4) JP2016517883A (enExample)
CN (1) CN105431163A (enExample)
AU (1) AU2014260468A1 (enExample)
BR (1) BR112015027682A2 (enExample)
CA (1) CA2911309A1 (enExample)
ES (1) ES2745532T3 (enExample)
MX (2) MX379043B (enExample)
RU (1) RU2015151216A (enExample)
SG (2) SG11201509012QA (enExample)
WO (2) WO2014178892A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
CA3035502A1 (en) 2014-04-30 2015-11-05 Kannan Rangaramanujam Dendrimer compositions and their use in treatment of diseases of the eye
WO2016025741A1 (en) 2014-08-13 2016-02-18 The Johns Hopkins University Selective dendrimer delivery to brain tumors
JP7088473B2 (ja) * 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
WO2017185083A1 (en) * 2016-04-22 2017-10-26 Viking Therapeutics Use of thyroid beta-agonists
WO2017185087A1 (en) 2016-04-22 2017-10-26 Viking Therapeutics Use of thyroid beta-agonists
DK3457851T3 (da) * 2016-05-18 2021-09-20 Univ Oregon Health & Science Derivater af sobetirom
KR102537274B1 (ko) * 2016-08-12 2023-05-25 오레곤 헬스 앤드 사이언스 유니버시티 아마이드 화합물, 이의 약학 조성물 및 이들을 이용하는 방법
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
WO2018201007A2 (en) 2017-04-27 2018-11-01 The Johns Hopkins University Dendrimer compositions for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
EP3644983B1 (en) 2017-06-29 2023-10-25 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
CN110891583B (zh) 2017-07-18 2023-06-06 学校法人庆应义塾 针对Th1细胞诱导性细菌的抗菌组合物
CA3082121C (en) 2017-11-10 2023-01-24 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
WO2020123861A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113784950A (zh) 2019-03-01 2021-12-10 速通医疗公司 新型拟甲状腺素药
AU2020391467A1 (en) 2019-11-29 2022-06-23 Autobahn Therapeutics, Inc. Novel thyromimetics
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DE69636677D1 (de) 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
JP2002519340A (ja) 1998-06-30 2002-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 甲状腺ホルモン類似体およびそれらの調製方法
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
JP2007505837A (ja) * 2003-09-15 2007-03-15 オードウェイ リサーチ インスティテュート 甲状腺ホルモンアナログおよび新脈管形成における使用の方法
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
AU2005284879B2 (en) 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
SG178002A1 (en) * 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
PT2187882E (pt) 2007-07-11 2013-04-17 Medicinova Inc Tratamento de uma doença neurodegenerativa progressiva com ibudilast
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
CN102612363A (zh) 2009-05-20 2012-07-25 舌交付有限公司 口腔和/或舌下治疗制剂
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
BR112015009313B1 (pt) * 2012-10-25 2021-03-23 Volvo Truck Corporation Sistema de freio pneumático controlado eletronicamente para um veículo automotivo, veículo automotivo equipado com um tal sistema e método para controle de um tal sistema
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Also Published As

Publication number Publication date
WO2014178892A8 (en) 2015-12-17
AU2014260468A1 (en) 2015-11-19
EP2991670A4 (en) 2017-01-18
MX2021000538A (es) 2021-04-28
JP2018162321A (ja) 2018-10-18
US20200405669A1 (en) 2020-12-31
SG11201509012QA (en) 2015-11-27
JP6360552B2 (ja) 2018-07-18
JP2018141024A (ja) 2018-09-13
JP2016517884A (ja) 2016-06-20
RU2015151216A (ru) 2017-06-08
MX2015015228A (es) 2016-10-03
WO2014178931A8 (en) 2015-11-26
HK1222552A1 (en) 2017-07-07
WO2014178892A1 (en) 2014-11-06
BR112015027682A2 (pt) 2017-08-29
EP2991670B1 (en) 2019-07-03
MX379043B (es) 2025-03-10
US10226438B2 (en) 2019-03-12
US11510887B2 (en) 2022-11-29
SG10201709090UA (en) 2017-12-28
US20160081955A1 (en) 2016-03-24
JP6360552B6 (ja) 2018-08-15
EP2991670B8 (en) 2019-09-11
US20190175531A1 (en) 2019-06-13
ES2745532T3 (es) 2020-03-02
EP2991670A1 (en) 2016-03-09
JP2016517883A (ja) 2016-06-20
CN105431163A (zh) 2016-03-23
WO2014178931A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
US11510887B2 (en) Sobetirome in the treatment of myelination diseases
US20170326145A1 (en) Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
US12594255B2 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
FR2807660A1 (fr) Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US9956202B2 (en) Use of indolyl and indolinyl hydroxamates for treating neurodegenerative disorders or cognitive decicits
WO2023034115A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
CN110248650A (zh) 用于增强突触发生和神经突发生的方法
JP6529634B1 (ja) アミロイドβ分解排出促進剤
US8557310B2 (en) Composition to retard the onset of symptoms of alzheimer's disease
US20230165810A1 (en) Fenfluramine for treatment of conditions associated with spreading depolarization
WO2020250182A2 (ko) 지페노사이드 화합물을 유효성분으로 포함하는 퇴행성 신경질환 치료용 조성물
US20210369720A1 (en) Synergistic composition having neuroprotective properties and methods of use thereof
US11458160B2 (en) Food supplements for use in the prophylaxis and treatment of migraine
HK1222552B (en) Sobetirome in the treatment of myelination diseases
TWI726355B (zh) 苯甲酸或其鹽及衍生物用於預防或治療抗n-甲基-d-天冬胺酸受體腦炎之用途
KR102804780B1 (ko) 인지기능 장애의 치료용 조성물
RU2631887C2 (ru) Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения демиелинизирующих заболеваний живого организма, включая профилактику заболевания
WO2013049523A1 (en) Methods for reducing a-beta-1-42 levels, methods for reducing or preventing formation of amyloid plaques, and methods for improving cognitive function and memory retention in a subject
CA3102371C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis
RU2345763C1 (ru) Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин
US20190269633A1 (en) Composition for prevention or treatment of chronic pain comprising evans blue
KR20160018806A (ko) 연하장애 개선용 의약품
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia
HK1155659A1 (en) Pharmaceutical composition for treatment of fibromyalgia

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200205